You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 29, 2024

Details for Patent: 8,212,033


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,212,033
Title:Use of substituted quinazoline compounds in treating angiogenesis-related diseases
Abstract:Quinazoline derivatives of the following formula:
Inventor(s):Su Wei-Guo, Zhang Weihan, Yan Xiaoqiang, Cui Yumin, Ren Yongxin, Duan Jifeng
Assignee:Hutchison Medipharma Enterprises Limited
Application Number:US12893872
Patent Claim Types:
see list of patent claims
 

Drugs Protected by US Patent 8,212,033

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Takeda Pharms Usa FRUZAQLA fruquintinib CAPSULE;ORAL 217564-001 Nov 8, 2023 RX Yes No ⤷  Try a Trial ⤷  Try a Trial TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER WHO HAVE BEEN PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN-, AND IRINOTECAN-BASED CHEMOTHERAPY, ANTI-VEGF THERAPY, AND, IF RAS WILD-TYPE AND MEDICALLY APPROPRIATE, ANTI-EGFR THERAPY ⤷  Try a Trial
Takeda Pharms Usa FRUZAQLA fruquintinib CAPSULE;ORAL 217564-002 Nov 8, 2023 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER WHO HAVE BEEN PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN-, AND IRINOTECAN-BASED CHEMOTHERAPY, ANTI-VEGF THERAPY, AND, IF RAS WILD-TYPE AND MEDICALLY APPROPRIATE, ANTI-EGFR THERAPY ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,212,033

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2009244130 ⤷  Try a Trial
Brazil PI0908675 ⤷  Try a Trial
Canada 2723148 ⤷  Try a Trial
Cyprus 1117222 ⤷  Try a Trial
Denmark 2297115 ⤷  Try a Trial
European Patent Office 2297115 ⤷  Try a Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.